1
Lalitha Krishnan, Richard A Leese, Raghavan Krishnan: Method for selective extracting a 7-(hydrogen or substituted amino)-9-�(substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound. American Cyanamid Company, T S Szatkowski, October 7, 1997: US05675030 (41 worldwide citation)

The invention provides a method for selectively extracting a compound of formula I: ##STR1## wherein: R is hydrogen or --NR.sub.3 R.sub.4 ; and when R=--NR.sub.3 R.sub.4, R.sub.3 and R.sub.4 may be the same or different and are selected from hydrogen and straight or branched (C.sub.1 -C.sub.4)alkyl; ...


2
Bart J Zoltan, Richard A Leese: Thermal control means for liquid chromatograph samples. American Cyanamid Company, Robert P Raymond, January 26, 1982: US04312835 (19 worldwide citation)

A Peltier effect thermal control sample containment means for an automatic sample holding apparatus used in conjunction with a liquid chromatograph analysis. The apparatus provides for the cooling or heating of a plurality of liquid chromatography samples and the maintenance of said samples at speci ...


3
Donald B Borders, William V Curran, Amedeo A Fantini, Noreen D Francis, Howard Jarolmen, Richard A Leese: Derivatives of laspartomycin and preparation and use thereof. Micrologix Biotech, Seed Intellectual Property Law Group PLLC, January 28, 2003: US06511962 (6 worldwide citation)

The present invention provides a laspartomycin core peptide, a laspartomycin core peptide derivative, a antimicrobial laspartomycin derivative, a method for making laspartomycin core peptides, methods for making laspartomycin core peptide derivatives, methods for making antimicrobial laspartomycin d ...


4
William V Curran, Christopher M Liu, Amy C D Bombardier, Richard A Leese, You Seok Hwang, Blaise S Lippa, Yanzhi Zhang: Antibiotic compositions for the treatment of gram negative infections. BioSource Pharm, Cubist Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, April 9, 2013: US08415307 (3 worldwide citation)

Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Als ...


5
Richard A Leese: Antibiotic compositions for the treatment of gram negative infections. Biosource Pharm, Hamilton Brook Smith & Reynolds P C, January 1, 2013: US08343912 (3 worldwide citation)

Provided herein is an antibacterial compound of the following formula: or a pharmaceutically acceptable salt thereof. The antibacterial compound has antibacterial properties against a diverse range of gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin B. Also provid ...


6
Dale R Cameron, Vincent A Boyd, Richard A Leese, William V Curran, Donald B Borders, Paulo W M Sgarbi, Shirley A Wacowich Sgarbi, Matthew Nodwell, Yuchen Chen, Qi Jia, Dominique Dugourd: Compositions of lipopeptide antibiotic derivatives and methods of use thereof. Biowest Therapeutics, Frommer Lawrence & Haug, Bruce E Black, January 11, 2011: US07868135 (2 worldwide citation)

The present invention provides derivatives of lipopeptide antibiotics that display antimicrobial activity against microorganisms, methods and compounds for synthesizing such antimicrobial derivatives and analogues, and methods of using the compounds in a variety of contexts, including in the treatme ...


7
Donald B Borders, William V Curran, Amedeo A Fantini, Noreen D Francis, Howard Jarolmen, Richard A Leese: Derivatives of laspartomycin and preparation and use thereof. Micrologix Biotech, Seed Intellectual Property Law Group PLLC, May 18, 2004: US06737403 (1 worldwide citation)

The present invention provides laspartomycin core peptides, laspartomycin core peptide derivatives, antimicrobial laspartomycin derivatives, methods for making laspartomycin core peptides, methods for making laspartomycin core peptide derivatives, methods for making antimicrobial laspartomycin deriv ...


8
William V Curran, Christopher M Liu, Amy C D Bombardier, Richard A Leese, You Seok Hwang, Blaise S Lippa, Yanzhi Zhang: Antibiotic compositions for the treatment of gram negative infections. BioSource Pharm, Cubist Pharmaceuticals, Hamilton Brook Smith & Reynolds P C, December 9, 2014: US08906866

Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Als ...


9
Richard A Leese: Antibiotic compositions for the treatment of gram negative infections. BioSource Pharm, Hamilton Brook Smith & Reynolds P C, January 20, 2015: US08937040

Provided herein is an antibacterial compound of the following formula: or a pharmaceutically acceptable salt thereof. The antibacterial compound has antibacterial properties against a diverse range of gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin B. Also provid ...


10
Richard A Leese, William V Curran, Donald B Borders: Lipodepsipeptide antibiotics and methods of preparation. BioSource Pharm, Stanley J Yavner, July 27, 2004: US06767718

Novel cyclodepsipeptide intermediates have been prepared from the A21978 complex and used to synthesize new lipodepsipeptide antibiotics. The three intermediates can be readily derivatized to give new families of antibiotics that have potent antibacterial activity against gram positive bacteria.